Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report report published on Tuesday. The firm issued a hold rating on the medical research company’s stock.

A number of other research firms have also commented on CTSO. EF Hutton Acquisition Co. I upgraded Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th.

Cytosorbents Price Performance

Shares of NASDAQ CTSO opened at $0.97 on Tuesday. The firm has a market cap of $53.04 million, a P/E ratio of -2.69 and a beta of 0.56. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $2.15. The business’s 50 day moving average is $1.08 and its 200-day moving average is $1.01.

Hedge Funds Weigh In On Cytosorbents

A number of hedge funds have recently added to or reduced their stakes in CTSO. Sargent Investment Group LLC increased its stake in shares of Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the last quarter. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents in the 3rd quarter valued at $51,000. Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Finally, CM Management LLC increased its stake in shares of Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.